News

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.

Melissa Magwire talks about why diabetes is a population health problem and a unique program at Saint Luke's that is helping patients across the nation.

KCTV talked to Melissa Magwire,RN, MSN, CDE, program director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence, to learn more about the Cardiometabolic Center.

Dr. Sanjaya Gupta, electrophysiologist at Saint Luke's Mid America Heart Institute, talks with KCTV about risk factors and new treatment available at Saint Luke's Atrial Fibrillation Clinic.

Through the Havertys' generosity, the Center has been able to create a national model of care called the Cardiometabolic Center Alliance.

Carmon is living with type 2 diabetes, but her life is much fuller now because of the care she received at Saint Luke’s Cardiometabolic Center of Excellence.